Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. B, 1998, Pages 57-62

  Brun Pascaud, M ^a   Chau, F ^a   Derouin, F ^b   Girard, P M ^c  

^a BICHAT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; MALOPRIM; ROXITHROMYCIN; SULFAMETHOXAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; LUNG INFECTION; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PARASITEMIA; PNEUMOCYSTIS CARINII; RAT; TOXOPLASMA GONDII;

EID: 0031946924     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_2.57     Document Type: Article

References (25)

1. Girdwood, R. W. A. (1989). 'Protozoan' infections in the immunocompromised patients-the parasites and their diagnosis. Journal of Medical Microbiology 30, 3-16.
2. Croft, S. L. (1995). Antiprotozoal drugs: some echoes, some shadows. In Society for General Microbiology Symposium 53, Fifty Years of Antimicrobials: Past Perspectives and Future Trends, (Hunter, P. A., Darby, G. K. & Russel, N. J., Eds), pp. 299-326. Cambridge University Press, Cambridge.
3. Edman, J. C., Edman, U., Cao, M., Lundgren, B., Kovacs, J. A. & Santi, D. V. (1989). Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proceedings of the National Academy of Sciences of the USA 86, 8625-9.
4. Matsumota, Y., Matsuda, S. & Tegoshi, T. (1989). Yeast glucan in the cyst wall of Pneumocystis carinii. Journal of Protozoology 36, S21-22.
5. Bartlett, M. S. & Smith, J. W. (1991). Pneumocystis carinii, an opportunist in immunocompromised patients. Clinical Microbiology Reviews 4, 137-49.
6. Cantin, L. & Chamberland, S. (1993). In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 37, 1993-6.
7. Barza, M. (1993). Animal models. In The New Macrolides, Azalides and Streptogramins (Neu, H. C., Young, L. & Zinner, S. H., Eds), pp. 49-60. Marcel Dekker, New York.
8. Durant, J., Hazime, F., Carles, M., Pechere, J.-C. & Dellamonica, P. (1995). Prevention of Pneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients. Infection 23, Suppl. 1, S33-8.
9. Hughes, W. T. & Killmar, J. T. (1991). Synergistic antiPneumocystis carinii effects of erythromycin and sulfisoxazole. Journal of Acquired Immune Deficiency Syndromes 4, 532-7.
10. Walzer, P. D., Foy, J., Steele, P. & White, M. (1992). Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrobial Agents and Chemotherapy 36, 1943-50.
11. Hofflin, J. M., Conley, F. K. & Remington, J. S. (1987). Murine model of intracerebral toxoplasmosis. Journal of infectious Diseases 155, 550-7.
12. Brun-Pascaud, M., Chau, F., Simonpoli, A.-M., Girard, P.-M., Derouin, F. & Pocidalo, J.-J. (1994). Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. Journal of Infectious Diseases 170, 653-8.
13. Brun-Pascaud, M., Girard, P.-M. & Pocidalo, J.-J. (1992). Low-dose trimethoprim-sulfamethoxazole alone and in association with zidovudine for the prevention and treatment of murine Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 36, 2328-30.
14. Gosey, L. L., Howard, R. M., Witebsky, F. G., Ognibene, F. P., Wu, T. C., Gill, V. J. et al. (1985). Advantages of a modified toluidine blue O stain and bronchoalveolar lavage for the diagnosis of Pneumocytsis carinii pneumonia. Journal of Clinical Microbiology 22, 803-7.
15. Piketty, C., Derouin, F., Rouveix, B. & Pocidalo J.-J. (1990). In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrobial Agents and Chemotherapy 34, 1467-72.
16. Inderlied, C. B. & Kemper, C. A. (1992). Disseminated Mycobacterium avium complex infection. AIDS Clinical Review, 131-72.
17. Dautzenberg, B., Truffot, C., Legris, S., Meyohas, M.-C., Berlie, H. C., Mercat, A. et al. (1991). Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune defiency syndrome. A controlled clinical trial. American Review of Respiratory Disease 144, 564-69.
18. Young, L. S., Bermudez, L. E., Wu, M. & Inderlied, C. B. (1995). Potential role of roxithromycin against the Mycobacterium avium complex. Infection 23, Suppl. 1, S28-32.
19. Struillou, L., Cohen, Y., Lounis, N., Bertrand, G., Grosset, J., Vilde, J.-L. et al. (1995). Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrobial Agents and Chemotherapy 39, 878-81.
20. Nilsen, O. G. (1995). Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin. Infection 23, Suppl. 1, S5-9.
21. Carbon, C. (1995). Clinical relevence of intracellular and extracellular concentrations of macrolides. Infection 23, Suppl. 1, S10-14.
22. Chang, H. R. & Pechere, J.-C. F. (1987). Effect of roxithromycin on acute toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 31, 1147-9.
23. Luft, B. J. (1987). In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice. European Journal of Clinical Microbiology 6, 479-81.
24. Araujo, F. G., Shepard, R. M. & Remington, J. S. (1991). In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. European Journal of Clinical Microbiology and Infectious Diseases 10, 519-24.
25. Hughes, W. T. (1989). Animal models for Pneumocystis carinii pneumonia. Journal of Protozoology 36, 41-5.